Healthcare

Capital solutions for every stage of growth

In collaboration with Mizuho's product specialists and Financial Sponsors team, we have led high-profile M&A and acquisition-financing deals as well as growth-stage financings. We provide clients a full suite of capabilities, including debt and equity offerings, leveraged finance, risk-focused derivative solutions, strategic advisory, corporate finance and working capital solutions.

Highlights

Provider of debt and equity financing for some of the largest acquisitions across healthcare including Thermo Fisher’s pending acquisition of PPD, Baxter’s pending acquisition of Hill-Rom, Danaher’s purchase of GE BioPharma, Bristol-Myers Squibb’s acquisition of Celgene, Mylan’s merger with Upjohn to form Viatris, and AbbVie’s acquisition of Allergan
Strong equity franchise acting as bookrunner on IPOs of Nkarta, PPD, BridgeBio, Neon Therapeutics, and Xeris, as well as Secondary / Convertible Financings for Leap Therapeutics, Cytokinetics, Eloxx Pharmaceuticals, BridgeBio, and Xeris
Active M&A advisory business with recent buyside and sellside transactions for Gilead Sciences, DXC Technology, Halo Pharmaceuticals, and SK Capital; also acted as Capital Markets Advisor on eFFECTOR’s public merger with Locust Walk
Provider of credit to support acquisition financings for Bristol Myers Squibb, Cigna, AbbVie, Viatris and Teva Pharmaceuticals
Strong partnership with Financial Sponsors Group including financings for Medline, Parexel, and go private of Cambrex, AMRI and Envision
Strong record of providing clients with Deal Contingent Risk Solutions through partnership with our Risk Solutions and integrated M&A teams